Celsentri

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

maraviroc

Available from:

ViiV Healthcare B.V.

ATC code:

J05AX09

INN (International Name):

maraviroc

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Okužbe z virusom HIV

Therapeutic indications:

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable,.

Product summary:

Revision: 28

Authorization status:

Pooblaščeni

Authorization date:

2007-09-18

Patient Information leaflet

                                61
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/07/418/011
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
celsentri 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
62
PODATKI NA STIČNI OVOJNINI
Nalepka na plastenki - 25 mg filmsko obložene tablete
1.
IME ZDRAVILA
CELSENTRI 25 mg filmsko obložene tablete
maravirok
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 25 mg maraviroka.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje sojin lecitin: za dodatne informacije glejte navodilo za
uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
120 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Pred uporabo preberite priloženo navodilo!
Za peroralno uporabo.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
_ _
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
63
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/07/418/011
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
64
PODATKI NA ZUNANJI OVOJNINI
Škatla za plastenko - 75 mg filmsko obložene tablete
1.
IME ZDRAVILA
CELSENTRI 75 mg filmsko obložene tablete
maravirok
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 75 mg maraviroka.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje sojin lecitin: za dodatne inf
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
CELSENTRI 25 mg filmsko obložene tablete
CELSENTRI 75 mg filmsko obložene tablete
CELSENTRI 150 mg filmsko obložene tablete
CELSENTRI 300 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
CELSENTRI 25 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 25 mg maraviroka.
Pomožne snovi z znanim učinkom: ena 25 mg filmsko obložena tableta
vsebuje 0,14 mg sojinega
lecitina.
CELSENTRI 75 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 75 mg maraviroka.
Pomožne snovi z znanim učinkom: ena 75 mg filmsko obložena tableta
vsebuje 0,42 mg sojinega
lecitina.
CELSENTRI 150 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 150 mg maraviroka.
Pomožne snovi z znanim učinkom: ena 150 mg filmsko obložena tableta
vsebuje 0,84 mg sojinega
lecitina.
CELSENTRI 300 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 300 mg maraviroka.
Pomožne snovi z znanim učinkom: ena 300 mg filmsko obložena tableta
vsebuje 1,68 mg sojinega
lecitina.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
CELSENTRI 25 mg filmsko obložene tablete
Modra, bikonveksna, ovalna filmsko obložena tableta, velika
približno 4,6 mm x 8,0 mm, z vtisnjeno
oznako "MVC 25".
CELSENTRI 75 mg filmsko obložene tablete
Modra, bikonveksna, ovalna filmsko obložena tableta, velika
približno 6,74 mm x 12,2 mm, z
vtisnjeno oznako "MVC 75".
CELSENTRI 150 mg filmsko obložene tablete
Modra, bikonveksna, ovalna filmsko obložena tableta, velika
približno 8,56 mm x 15,5 mm z oznako
"MVC 150".
3
CELSENTRI 300 mg filmsko obložene tablete
Modra, bikonveksna, ovalna filmsko obložena tableta, velika
približno 10,5 mm x 19,0 mm, z
vtisnjeno oznako "MVC 300".
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo CELSENTRI je v kombinaciji z drugimi protiretrovirusnimi
zdravili indicirano za uporabo
pri odraslih, mladostnikih in otrocih, starih 2 leti ali ve
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-08-2022
Public Assessment Report Public Assessment Report Bulgarian 18-07-2017
Patient Information leaflet Patient Information leaflet Spanish 22-08-2022
Public Assessment Report Public Assessment Report Spanish 18-07-2017
Patient Information leaflet Patient Information leaflet Czech 22-08-2022
Public Assessment Report Public Assessment Report Czech 18-07-2017
Patient Information leaflet Patient Information leaflet Danish 22-08-2022
Public Assessment Report Public Assessment Report Danish 18-07-2017
Patient Information leaflet Patient Information leaflet German 22-08-2022
Public Assessment Report Public Assessment Report German 18-07-2017
Patient Information leaflet Patient Information leaflet Estonian 22-08-2022
Public Assessment Report Public Assessment Report Estonian 18-07-2017
Patient Information leaflet Patient Information leaflet Greek 22-08-2022
Public Assessment Report Public Assessment Report Greek 18-07-2017
Patient Information leaflet Patient Information leaflet English 22-08-2022
Public Assessment Report Public Assessment Report English 18-07-2017
Patient Information leaflet Patient Information leaflet French 22-08-2022
Public Assessment Report Public Assessment Report French 18-07-2017
Patient Information leaflet Patient Information leaflet Italian 22-08-2022
Public Assessment Report Public Assessment Report Italian 18-07-2017
Patient Information leaflet Patient Information leaflet Latvian 22-08-2022
Public Assessment Report Public Assessment Report Latvian 18-07-2017
Patient Information leaflet Patient Information leaflet Lithuanian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-08-2022
Public Assessment Report Public Assessment Report Lithuanian 18-07-2017
Patient Information leaflet Patient Information leaflet Hungarian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 22-08-2022
Public Assessment Report Public Assessment Report Hungarian 18-07-2017
Patient Information leaflet Patient Information leaflet Maltese 22-08-2022
Public Assessment Report Public Assessment Report Maltese 18-07-2017
Patient Information leaflet Patient Information leaflet Dutch 22-08-2022
Public Assessment Report Public Assessment Report Dutch 18-07-2017
Patient Information leaflet Patient Information leaflet Polish 22-08-2022
Public Assessment Report Public Assessment Report Polish 18-07-2017
Patient Information leaflet Patient Information leaflet Portuguese 22-08-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 22-08-2022
Public Assessment Report Public Assessment Report Portuguese 18-07-2017
Patient Information leaflet Patient Information leaflet Romanian 22-08-2022
Public Assessment Report Public Assessment Report Romanian 18-07-2017
Patient Information leaflet Patient Information leaflet Slovak 22-08-2022
Public Assessment Report Public Assessment Report Slovak 18-07-2017
Patient Information leaflet Patient Information leaflet Finnish 22-08-2022
Public Assessment Report Public Assessment Report Finnish 18-07-2017
Patient Information leaflet Patient Information leaflet Swedish 22-08-2022
Public Assessment Report Public Assessment Report Swedish 18-07-2017
Patient Information leaflet Patient Information leaflet Norwegian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 22-08-2022
Patient Information leaflet Patient Information leaflet Icelandic 22-08-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 22-08-2022
Patient Information leaflet Patient Information leaflet Croatian 22-08-2022
Public Assessment Report Public Assessment Report Croatian 18-07-2017

Search alerts related to this product

View documents history